DSIP
Delta Sleep-Inducing Peptide · DSIP Acetate
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit brain during induced sleep in 1977. Despite its name, DSIP does not directly induce sleep but rather modulates sleep architecture to promote delta wave (slow-wave) sleep, the deepest and most restorative phase of the sleep cycle. DSIP has an inherently short in vitro half-life (approximately 15 minutes in plasma) but achieves longer biological effects through complexing with carrier proteins in vivo. It acts through multiple neuroendocrine pathways including modulation of cortisol circadian rhythms, GABA receptor sensitivity, and serotonin metabolism. DSIP is commonly paired with Selank for a comprehensive sleep-anxiety support stack.
Bedtime dosing, 30-60 minutes before desired sleep. SubQ or intranasal. No fasting required. Delta-wave sleep inducer.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
DSIP modulates sleep architecture through several intersecting neuroendocrine pathways. It enhances GABAergic inhibitory tone to promote sleep onset and maintenance, normalizes cortisol circadian rhythm (reducing evening cortisol that interferes with sleep), modulates serotonin metabolism affecting sleep-wake transitions, and interacts with opioid receptor pathways involved in pain perception and stress modulation. DSIP does not function as a sedative or hypnotic; it does not force unconsciousness but rather shifts sleep architecture toward deeper, more restorative stages. The 15-minute in vitro half-life is misleading because DSIP forms complexes with carrier proteins (albumin, immunoglobulins) that serve as slow-release reservoirs, extending its effective biological window to several hours.
What to expect
Days 1-3: Many users report improved sleep quality within the first few nights. Delta wave promotion effects are relatively rapid. No morning grogginess at appropriate doses.
Weeks 1-4: Consistent sleep improvement. Cortisol rhythm normalization becomes established. Stress-sleep cycle begins to break. HRV overnight patterns may improve.
Weeks 4-8: Sustained sleep architecture improvements. Best assessed via sleep tracking (Oura, Whoop) showing increased deep sleep percentage and improved HRV.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Quick-start dose/route: 100-250 mcg SubQ nightly 1-2 hours before bed. No checked human abstract administered DSIP subcutaneously at this dose. PMID 7777652 used 3-4 mg intravenous infusions.
Mechanism: GABAergic tone, cortisol normalization, serotonin/opioid modulation, and carrier-protein slow release. No checked abstract supported this composite mechanism for subcutaneous DSIP; PMID 7777652 reported no ACTH/cortisol effect after IV DSIP.
Primary safety: morning grogginess, vivid dreams, injection-site irritation, and no dependence. No checked abstract established these safety claims for the displayed SubQ regimen.
The honest take
Delta wave sleep promotion
SupportedConfirmed by EEG studies in humans. The original discovery was based on EEG-documented delta wave induction. The strongest supported claim.
Human studies in chronic pain patients showed improved pain tolerance. Mechanism involves opioid receptor pathway interaction. Not a pain medication.
Animal and some human data show normalization of cortisol circadian rhythm. Relevant for stress-disrupted sleep patterns.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Side effects & safety
Commonly reported
- Generally well tolerated
- Mild morning grogginess if dose is too high
- Occasional vivid dreams
- Mild injection site irritation
Less common & notes
- DSIP is endogenously produced, suggesting good inherent tolerability.
- Rare reports of headache.
- No dependence or withdrawal reported.
- The inherent instability means potency decreases over time if not stored properly.
- Some users report paradoxical alertness at very low doses.
- Long-term data is limited.
Pharmacokinetics
SubQ
Carrier protein depot extends biological activity; delta wave sleep effects last through the night
Rapid enzymatic degradation (peptidases); carrier protein complexing extends effective duration; renal excretion
Storage. CRITICAL: DSIP is inherently unstable with a 15-minute in vitro plasma half-life. Reconstituted solution stability is 14-21 days refrigerated at 2-8C. Use within 2-3 weeks of reconstitution regardless of remaining volume. Do not attempt to extend beyond 3 weeks. Unreconstituted lyophilized powder is more stable (store frozen -20C). Protect from light and heat. The short shelf life is the primary practical challenge with DSIP.
Regulatory status
DSIP is not FDA-approved for any indication. Available as a research peptide. Not a controlled substance. WADA status: Not specifically listed. Available through research and compounding channels.
Put it to work
Calculate, log & track
Open DSIP straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open DSIP in the app →Go deeper
The guide & community
The complete DSIP walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗